Is NAD+ Legal? Global Regulatory Guide (2026)

Short answer: there is no single worldwide legal status for NAD+, NMN or NR. The relevant rules depend on the substance, product format, claims, route of administration, intended use and destination country. A laboratory reagent, an oral food supplement and an injectable product may be regulated very differently even when their names appear related.

Last reviewed: 24 September 2026. This guide is general regulatory information, not legal or medical advice.

On this page: NAD+, NMN and NR · How products are classified · United Kingdom · European Union · United States · Canada · Australia · Imports · Compliance checklist

NAD+, NMN and NR are not interchangeable legal terms

Nicotinamide adenine dinucleotide (NAD+) is a naturally occurring coenzyme. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are related precursors, but a regulator may treat each substance differently. A decision concerning NMN in food supplements does not automatically establish the status of NAD+ as a laboratory reagent, cosmetic ingredient, medicine or injectable product.

The product's presentation matters as much as its name. Regulators may consider the stated purpose, advertising claims, dose form, route of administration, composition, pharmacological effect and the way an ordinary customer would understand the product.

The first question is: what kind of product is it?

Presentation Likely regulatory question
Laboratory reagent or analytical reference material Is it genuinely supplied and marketed for non-human research, with no therapeutic, consumption or performance claims?
Food or oral supplement containing NMN, NR or another NAD-related ingredient Is the ingredient permitted for food use, and does it require novel-food or new-dietary-ingredient authorisation?
Injection, infusion or therapeutic presentation Is it an authorised medicine or other therapeutic good, and may it be supplied, prescribed or imported?
Cosmetic or topical product Does it meet cosmetic rules, and do its claims remain cosmetic rather than medicinal?

A disclaimer does not override the substance of a product page. Authorities can look at the whole presentation, including imagery, testimonials, implied benefits and instructions.

United Kingdom

The UK does not have one blanket rule covering every NAD-related product. The Medicines and Healthcare products Regulatory Agency (MHRA) decides whether a product is a medicine by considering factors including its claims, pharmacological properties, intended purpose, presentation and similarity to licensed medicines. The MHRA's borderline-products guidance explains this case-by-case approach.

Products presented to treat or prevent disease, or to modify physiological functions through pharmacological action, can fall within medicines law. Food and supplement products are subject to a different framework. A research-only NAD+ reagent should therefore be presented consistently as a research product and should not include human-use directions or therapeutic claims.

European Union

EU rules also depend on classification. For food use, the European Commission's novel-food process is particularly relevant. An official consultation concluded that NMN of 95–99% purity intended for food supplements and fortified foods is a Novel Food. Novel foods generally require pre-market authorisation and inclusion in the EU Union list before lawful food marketing.

That NMN food decision is important but narrow: it does not automatically determine the status of NAD+ laboratory materials, cosmetics or medicinal presentations. Medicines and borderline-product decisions may also involve national authorities in the destination member state.

United States

In the United States, classification depends on intended use and regulatory category. The FDA explains that dietary supplements are products intended to supplement the diet, while an article approved as a new drug—or authorised for substantial clinical investigation in certain circumstances—may be excluded from the dietary-supplement definition unless it was previously marketed as a food or supplement. See the FDA's dietary supplement questions and answers.

Disease-treatment claims or therapeutic presentation can cause a product to be regulated as a drug. The FDA warns that unapproved drugs have not undergone its review for safety, effectiveness or quality. See FDA concerns about unapproved drugs. This guide does not treat the status of one NAD-related ingredient as a universal answer for all NAD+, NMN or NR products.

Canada

Health Canada regulates products according to their composition, claims, format and intended use. In an April 2026 advisory, Health Canada reported seizure of unauthorised injectable products—including products labelled NAD+—and warned that a “research use only” statement does not create an exemption when a product is represented or sold for human use. See the official Health Canada public advisory.

This does not mean every laboratory NAD+ material is automatically treated as an injectable drug. It does show why format, sales context and claims must be assessed together.

Australia

Australia regulates products presented for therapeutic use as therapeutic goods. Products generally need to comply with the Therapeutic Goods Act and, unless an exemption applies, be entered in the Australian Register of Therapeutic Goods before supply. Importation can be subject to separate conditions.

The Therapeutic Goods Administration's guidance on importing and supplying unapproved products illustrates the regulator's approach to unapproved therapeutic presentations and personal importation. Although that advisory focuses on peptide products, the same core point matters for NAD-related products: calling a product a wellness or research product does not control its legal classification when its presentation indicates therapeutic use.

Import and customs rules are a separate question

A product that may be possessed or sold in one context is not automatically permitted to cross a border. Customs authorities can examine the substance, quantity, documentation, intended use and destination-country rules. Personal-import schemes, where available, often have strict conditions and do not authorise commercial supply.

Before an international order, check the destination regulator and customs authority. Do not assume that a supplier's research-only wording guarantees clearance.

What “research use only” does—and does not—mean

Research-only labelling can accurately describe a genuine laboratory product. It is not a legal shield and does not convert a consumer, supplement or therapeutic product into a laboratory reagent. Consistency matters: the product description, supporting content, packaging, imagery and customer communications should all avoid human-use instructions and therapeutic or performance claims.

Practical compliance checklist

  • Identify the exact substance: NAD+, NMN, NR or another related compound.
  • Define the product category and intended use before making claims.
  • Check food, supplement, medicine, cosmetic and import rules separately.
  • Use official regulator sources for the destination country.
  • Keep research products free from dosage, administration, treatment and performance guidance.
  • Recheck the rules before purchase or import; regulatory positions can change.

Related NutriMax resources

Important notice

This page provides general information and is not legal advice. Rules can change and may depend on facts not covered here. Consult the relevant regulator or a qualified legal adviser before supplying, importing or purchasing a regulated product.

Supplied for research purposes only. Not for human consumption.